Clinical trials: Hematological Malignancies
Platelet Transfusion, Palliative Care
Retrospective Descriptive Study of Platelet Transfusion in Patients With Palliative Hematologic Malignancies at the University Hospital of Besançon
Development of palliative care is less effective for patients with hematologic malignancies. Limited data is available for end of life care in this population, moreover with thrombocytopenic patients.
- Trial name
- NCT03814486
- Testing
- descriptive
- Where
- France
- Volunteers
- 119 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer
This clinical trial studies fludarabine phosphate, low-dose total body irradiation, and donor stem cell transplant in treating patients with hematologic malignancies or kidney cancer.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00005799
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 7 sites in United States, Germany
- Volunteers
- 55 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematologic Malignancies
IVIG for Infection Prevention After CAR-T-Cell Therapy
This phase II trial compares the effects of immunoglobulin replacement therapy with a placebo for preventing infectious complications in patients receiving CD19 chimeric antigen receptor (CAR)-T cell therapy.
- Trial name
- NCT05952804
- Testing
- Immune Globulin Infusion (Human), 10% Solution, Anti-CD19 CAR T Cells Preparation, Saline
- Where
- 7 sites in United States
- Volunteers
- 150 people
- Sponsor
- Fred Hutchinson Cancer Center
Solid Tumors, Chronic Lymphocytic Leukemia
A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
This is a four-part dose-escalation and confirmation study in participants with advanced solid tumors. Part A is for dose escalation and determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of…
- Conditions
- Solid Tumors, Chronic Lymphocytic Leukemia, T-cell-prolymphocytic Leukemia
- Trial name
- NCT00749502
- Testing
- MK-4827
- Volunteers
- 113 people
- Sponsor
- Tesaro, Inc.
Advanced Cancer, Solid Tumor
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used…
- Conditions
- Advanced Cancer, Solid Tumor, Haematological Malignancy
- Trial name
- FINPROVE (NCT05159245)
- Testing
- Alectinib, Cobimetinib, Vismodegib
- Where
- 5 sites in Finland
- Volunteers
- 250 people
- Sponsor
- Helsinki University Central Hospital
Hematologic Neoplasms, Neutropenia
Umbilical Cord Derived Mesenchymal Stem Cells for Treatment-induced Myelosuppression in Hematologic Malignancies
The purpose of the study is to explore the safety and efficacy of umbilical cord derived mesenchymal stem cells in treatment-induced myelosuppression in patients with hematologic malignancies.
- Conditions
- Hematologic Neoplasms, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- NCT05672420
- Testing
- umbilical cord derived mesenchymal stem cells
- Where
- 3 sites in China
- Volunteers
- 181 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Polycythemia Vera
Dasatinib in Polycythemia Vera
The purpose for conducting this research study is to determine the feasibility of using dasatinib as a treatment for polycythemia vera and to determine the optimum treatment regimen.
- Trial name
- NCT00538980
- Testing
- Dasatinib
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Weill Medical College of Cornell University
B-lymphoid Malignancies, Chronic Lymphocytic Leukemia
Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
- Conditions
- B-lymphoid Malignancies, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT00446342
- Testing
- SNS-032 Injection
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Sunesis Pharmaceuticals
Leukemia, Lymphoma
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00006042
- Testing
- filgrastim, cyclophosphamide, fludarabine phosphate
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Essential Thrombocythemia (ET), Myelofibrosis (MF)
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
In this study the aim is to investigate the pathogenetic role of extracellular vesicles and senescence in Myeloproliferative Neoplasms.
- Conditions
- Essential Thrombocythemia (ET), Myelofibrosis (MF), Polycythemia Vera (PV)
- Trial name
- NCT06798805
- Where
- 5 sites in Italy
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Breast Cancer, Prostate Cancer
Lighting Intervention for Cancer-related Fatigue
Fatigue is a major problem for cancer patients, and one that can persist long after treatment ends. Recent work has demonstrated that light therapy may mitigate or reduce fatigue levels in both cancer patients and cancer…
- Conditions
- Breast Cancer, Prostate Cancer, Hematologic Malignancy, Survivorship
- Trial name
- NCT04827446
- Testing
- Wearable Sensor, Blue-blocking glasses, Clear glasses
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- University of Michigan Rogel Cancer Center
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis
- Trial name
- NCT00255346
- Testing
- Dasatinib (BMS-354825)
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm
Effect of the COVID-19 Public Health Crisis on the Mental Health and Physical Well-Being of Cancer Patients, the Coping With COVID Study
This study determines how the threat of the coronavirus has affected the mental health and physical well-being of cancer patients seen at the psychiatric oncology clinic, and how they have coped with any related stress.
- Conditions
- COVID-19 Infection, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04652505
- Testing
- Questionnaire Administration
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Transplant, Myeloma
Study Evaluating SARS-CoV-2 (COVID-19) Humoral Response After BNT162b2 Vaccine in Immunocompromised Adults Compared to Healthy Adults
The primary endpoint of this study is to compare the humoral response (titre and neutralizing capacity of induced antibodies) against SARS-CoV-2 following vaccination with BNT162b2 (Pfizer BioNTech) in immunocompromised persons…
- Conditions
- Kidney Transplant, Myeloma, Cancer, Hematologic Malignancy
- Trial name
- EREVA (NCT04952766)
- Testing
- Biological samples
- Where
- France
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Régional d'Orléans
Hematologic Malignancies, Adult
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
The goal of this clinical trial is to learn if KQB198 works to treat advanced hematologic malignancies in adults. It will also learn about the safety of KQB198.
- Trial name
- NCT06645886
- Testing
- KQB198, Dasatinib
- Where
- 29 sites in United States, France and 6 more
- Volunteers
- 13 people
- Sponsor
- Kumquat Biosciences Inc.
Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma
PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
This is a Phase 1 dose-escalation study of PRT1419, a myeloid cell leukemia-1 (MCL-1) inhibitor, in participants with selected relapsed/refractory myeloid or B-cell malignancies.
- Conditions
- Acute Myeloid Leukemia, B-cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05107856
- Testing
- PRT1419, Azacitidine, Venetoclax
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Prelude Therapeutics Incorporated
Hematologic Malignancy, Lymphoma
Telerehabilitation in Hemato-oncological Survivors
This study investigates whether the 12-week home-based exercise training with remote guidance and telemonitoring compared to regular center-based training leads to better long-term cardiorespiratory fitness and physical activity…
- Trial name
- Tele@home (NCT05779605)
- Testing
- Home-based training, Center-based training
- Where
- Czechia
- Volunteers
- 80 people
- Sponsor
- Brno University Hospital
Hematopoietic and Lymphatic System Neoplasm
Sustained Oral Fiber Supplementation for Patients Undergoing Treatment for Hematological Malignancies
This clinical trial examines sustained oral fiber supplementation for patients undergoing treatment for hematological malignancies.
- Trial name
- NCT04829136
- Testing
- Kate Farms 1.0, Standard of Care Nutritional Support, Survey Administration
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelofibrosis, Polycythemia Vera
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
To determine the safety, tolerability and effectiveness of ruxolitinib (INCB018424), administered orally to patients with Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) and Essential Thrombocythemia…
- Conditions
- Myelofibrosis, Polycythemia Vera, Thrombocytosis
- Trial name
- NCT00509899
- Testing
- Ruxolitinib
- Where
- 2 sites in United States
- Volunteers
- 154 people
- Sponsor
- Incyte Corporation
Hematological Malignancy, Hematopoetic Stem Cell Transplantation
Middle East Study of Infections in Patients With Hematological Malignancies
The goal of this prospective observational study is to is to prospectively study the epidemiology of bloodstream infection (BSI) in patients with hematological malignancies (HM) and hematopoietic stem cell transplant (HSCT)…
- Conditions
- Hematological Malignancy, Hematopoetic Stem Cell Transplantation, Bloodstream Infection
- Trial name
- MESI-HM (NCT07900542)
- Testing
- No Intervention: Observational Cohort
- Where
- 9 sites in Jordan, Oman and 3 more
- Volunteers
- 1,000 people
- Sponsor
- Hamad Medical Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.